In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BerGenBio AS (BRRGF), with a price target of NOK66.00. The company’s shares closed last Thursday at $3.94, close to its 52-week high of $4.39.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 44.1% and a 67.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BerGenBio AS with a $7.31 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.39 and a one-year low of $1.23. Currently, BerGenBio AS has an average volume of 110.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
